ACCELERET
29 Nov 2021
AcceleRET-Lung
NCT04222972
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Metastatic or Widespread |
Anticipated Start Date | 2020-07-24 |
Anticipated End Date | 2023-09-30 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Hannah Adelson |
Hannah.adelson@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Professor Chris Karapetis |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs